BETHESDA, Md., and ZURICH, Switzerland, June 24 Micromet,Inc. (Nasdaq: MITI) and Nycomed today announced the initiation of formalpreclinical safety studies for the anti-GM-CSF human antibody MT203.
Preclinical studies with MT203 provided evidence of activity in inflammatory and autoimmune diseases. Micromet received €1.5 million, or $2 million, as a milestone payment from Nycomed, which filed ...
MT203 being investigated for treatment of inflammatory and autoimmune diseases. Micromet and Nycomed will collaborate on the development of anti-GM-CSF antibodies that may be useful for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results